X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Decision to terminate enrollment in davoceticept (ALPN-202) conditional CD28 costimulator and dual checkpoint inhibitor studies was made in interest of patient safety after the Company was notified of a second death in the NEON-2 study, attributed to cardiogenic shock.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 24, 2022
Details:
ALPN-303, a best-in-class dual B cell cytokine antagonist being developed for the treatment of B cell mediated inflammatory and autoimmune diseases, and davoceticept (ALPN-202), a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Davoceticept (ALPN-202) , first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for treatment of cancer. Preclinical studies of davoceticept have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Davoceticept (ALPN-202) is first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor intended for treatment of cancer. Preclinical studies of davoceticept have demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
ALPN-202 (Davoceticept), a first-in-class, CD28 costimulator and dual checkpoint inhibitor intended for treatment of cancer. Preclinical studies of davoceticept have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
ALPN-202 (davoceticept), a first-in-class, conditional CD28 costimulator and dual checkpoint inhibitor is engineered to provide direct T cell costimulation and dual checkpoint inhibition to enable immune system to mount a robust anti-tumor response.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The partial clinical hold was prompted by Alpine’s report of a Grade 5 serious adverse event in the NEON-2 trial, evaluating davoceticept (ALPN-202) in combination with pembrolizumab in adults with advanced malignancies.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2022
Details:
The collaboration will evaluate the safety and efficacy of Alpine’s ALPN-202, a first-in-class conditional CD28 costimulator and dual checkpoint inhibitor, in combination with Merck’s anti-PD-1 therapy KEYTRUDA, the first anti-PD-1 therapy approved in the U.S.
Lead Product(s): Davoceticept,Pembrolizumab
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alpine Immune Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2021
Details:
ALPN-202 has been generally well-tolerated as of the data cutoff date. The most common treatment-related adverse events have included immune-related toxicities, particularly cutaneous reactions.
Lead Product(s): Davoceticept
Therapeutic Area: Oncology Product Name: ALPN-202
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 04, 2021
Details:
Preclinical studies of ALPN-202 have successfully demonstrated superior efficacy in tumor models compared to checkpoint inhibition alone. A phase 1 trial of ALPN-202 in advanced malignancies (NEON-1, NCT04186637) is open for enrollment.
Lead Product(s): Davoceticept
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Poster will highlight first-in-human phase I open-label study of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.
Lead Product(s): Davoceticept
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
